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The prevalence of influenza A and B virus-specific IgG 
was determined in sera taken between 2008 and 2010 
from 1,665 children aged 0–17 years and 400 blood 
donors in Germany. ELISA on the basis of whole virus 
antigens was applied. Nearly all children aged nine 
years and older had antibodies against influenza A. In 
contrast, 40% of children aged 0–4 years did not have 
any influenza A virus-specific IgG antibodies. Eighty-
six percent of 0–6 year-olds, 47% of 7–12 year-olds 
and 20% of 13–17 year-olds were serologically naïve to 
influenza B viruses. By the age of 18 years, influenza 
B seroprevalence reached approximately 90%. There 
were obvious regional differences in the seropreva-
lence of influenza B in Germany. In conclusion, sero-
prevalences of influenza A and influenza B increase 
gradually during childhood. The majority of children 
older than eight years have basal immunity to influ-
enza A, while comparable immunity against influenza 
B is only acquired at the age of 18 years. Children aged 
0–6 years, showing an overall seroprevalence of 67% 
for influenza A and of 14% for influenza B, are espe-
cially at risk for primary infections during influenza B 
seasons.
Introduction
Influenza is a major public health threats worldwide 
with approximately 1 billion of the total population 
infected annually, resulting in 5 million serious dis-
eases and 500,000 deaths [1]. Children are one of the 
most vulnerable groups since they are often immuno-
logically naïve when placentally transferred antibodies 
have disappeared after ca one year of life [2], and the 
contacts made by children favour infections by the res-
piratory route [3]. Thus, influenza has been shown to 
be an important cause of morbidity during childhood, 
with attack rates ranging from 20% to 30% during 
epidemics [4]. Furthermore, infants and children with 
underlying disease are at increased risk of severe influ-
enza and influenza-associated mortality [5-7]. Several 
studies have shown that influenza in childhood has 
considerable socioeconomic impact on the children’s 
households [4,8,9] because children are regarded as 
the main and most efficient transmitters for spreading 
influenza in the community.
The most effective existing intervention to prevent 
morbidity and mortality of children due to influenza 
is the annual vaccination against seasonal influenza 
[10]. A study in Germany has shown that 50% of severe 
influenza cases in paediatric intensive care units might 
have been prevented if the current recommendations 
for vaccination, which only include risk groups of chil-
dren, had been followed [6]. As demonstrated in several 
randomised clinical trials, intranasal live attenuated 
influenza vaccine has higher efficacy than the stand-
ard inactivated split vaccine and may improve vaccina-
tion in children [11,12]. However, owing to variations in 
circulating virus strains and in children’s immune sys-
tems, current influenza vaccines are not fully protec-
tive [13]. Immunologically naïve younger children may 
be at increased risk of severe influenza disease and 
will therefore benefit from vaccination more than older 
children who have already had one or more influenza 
virus infections. This may explain why hospitalisation 
rates related to influenza virus infections are high in 
young children and comparable to those observed in 
adults over 60 years [14-16]. Therefore, seroepidemio-
logical data on influenza A and B during childhood as 
a surrogate for type-specific priming are a fundamen-
tal prerequisite for the development of efficacious 
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vaccination policies for children. To date, the available 
data are scarce, and restricted to regional sampling 
points [2] or virus strain-specific tests [17,18]. The 
seroprevalence against influenza A and B, determined 
by sensitive and specific type-specific ELISA, may be 
a good surrogate marker for immunological priming 
since strain-specific assays such as the haemagglu-
tination inhibition test depend on carefully selected 
panels of virus antigens and may underestimate the 
true seroprevalence.
Here, we describe a multicentre seroepidemiological 
study to determine influenza A and B antibody preva-
lence in infants, children and adolescents in Germany. 
Sera were obtained between 2008 and 2010 from nine 
paediatric and diagnostic centres throughout Germany. 
To compare these data with the influenza seropreva-
lence in adults, sera from blood donors were included. 
For the determination of influenza A- and B-specific IgG 
antibodies, type-specific ELISA with high sensitivity 
and specificity was used.
Methods
Patients and serum samples
A total of 1,665 sera from children aged one month to 
17 years and 400 sera from blood donors aged 18 to 65 
years were included. Sera of children were collected pri-
marily between 2008 and 2010 from eight German pae-
diatric primary care hospitals (Bremen, Berlin, Krefeld, 
Wuppertal, Erfurt, Würzburg, Mannheim, Munich) and 
one diagnostic institute (Ulm) for seroprevalence stud-
ies of pandemic influenza A [19]. Children with an ill-
ness impeding an adequate immune response were 
excluded. Some 15.8% (220/1,396) of children had 
been vaccinated against seasonal influenza and 7.1% 
(99/1,396) against pandemic influenza A between 
2008 and 2010, but the reasons were unknown. This 
means that the vaccination was carried out in the same 
year or one year before the sample was taken. Sera 
of blood donors aged 18 to 65 years were collected 
anonymously between 2010 and 2011 mainly in North-
Rhine Westphalia (German Red Cross blood donation 
centre Muenster, 337/400, 84.3%) and in Lower Saxony 
(German Red Cross blood donation centre Springe, 
63/400, 15.7%) and there was no information about the 
donors’ vaccination status against influenza. However, 
an average vaccination rate of 15–20% can be assumed 
[20]. 
In accordance to recommendations of the Central 
Ethical Committee of Germany [21], patient consent 
is not required for studies on anonymised residual 
samples. The Ethical Committee of the Jena University 
approved the study protocol.
Testing of sera
Sera were stored in aliquots at −20 °C without interrup-
tion until testing. All sera were brought to room tem-
perature immediately before testing. Antibody testing 
was carried out blindly in groups of 90 serum samples. 
Sera were tested in parallel using influenza virus A IgG 
Table 1
Prevalence of IgG antibodies against influenza A virus in children (aged 0–17 years, n=1,664a) and adults (blood donors aged 
18–65 years, n=400), Germany, 2008–11
Age group 
in years
Male Female Male and female
Number of positive 
samples/total 
number
Percentage (95% 
CI)
Number of positive 
samples/total 
number
Percentage (95% 
CI)
Number of positive 
samples/total 
number
Percentage (95% 
CI)
Infants, children and adolescents
0–2 71/150 47.3 (39.1–55.6) 55/121 45.4 (36.4–54.8) 126/271 46.5 (40.4–52.6)
3–4 81/104 77.9 (68.7–85.4) 59/71 83.1 (72.3–91.0) 140/175 80.0 (73.3–85.7)
5–6 64/74 86.5 (76.6–93.3) 71/77 92.2 (83.8–97.1) 135/151 89.4 (83.4–93.8)
7–8 86/89 96.6 (90.5–99.3) 82/86 95.3 (88.5–98.7) 168/175 96.0 (91.9–98.4)
9–10 95/97 97.9 (92.8–99.8) 95/95 100.0 (96.2–100.0) 190/192 99.0 (96.3–99.9)
11–12 100/100 100.0 (96.4–100.0) 101/101 100.0 (96.4–100.0) 201/201 100.0 (98.2–100.0)
13–14 112/112 100.0 (96.8–100.0) 111/112 99.1 (95.1–100.0) 223/224 99.6 (97.5–100.0)
15–17 113/113 100.0 (96.8–100.0) 162/162 100.0 (97.8–100.0) 275/275 100.0 (98.7–100.0)
Total 722/839 86.1 (83.5–88.3) 736/825 89.2 (86.9–91.2) 1,458/1,664 87.6 (85.9–89.2)
Adults (blood donors)
18–29 78/79 98.7 (93.3–100.0) 72/72 100.0 (95.0–100.0) 150/151 99.3 (96.4–100.0)
30–45 67/72 93.1 (84.5–97.7) 52/52 100.0 (93.2–100.0) 119/124 96.0 (90.8–98.7)
46–65 71/78 91.0 (82.4–96.3) 45/47 95.7 (85.5–99.5) 116/125 92.8 (86.8–96.7)
Total 216/229 94.3 (90.5–96.9) 169/171 98.8 (95.8–99.9) 385/400 96.3 (93.9–97.9)
a For one patient, there was only enough serum to perform the test against influenza B.
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ELISA (IBL International, Hamburg, Germany) and influ-
enza virus B IgG ELISA (Euroimmun, Lübeck, Germany). 
These two ELISAs had been selected as the most sen-
sitive and specific tests after comparing different com-
mercially available ELISAs for influenza A and B IgG. 
Testing of defined serum samples from children [2], 
newborns and their mothers [22] by several commer-
cial ELISAs, including the haemagglutination inhibition 
assay [23], revealed sensitivities ≥97% and no cross-
reactivities between influenza A and B virus or to other 
viral pathogens for the ELISAs used in this study. Both 
ELISAs were carried out manually and used for quali-
tative and semi-quantitative antibody testing. All sam-
ples were tested twice on different days, and sera with 
the same qualitative results were included in this study 
without retesting. Samples with discordant qualitative 
results were retested twice, and the most frequent 
result, including the original test result, was accepted. 
The influenza virus A IgG ELISA used whole inac-
tivated influenza virus A Sydney/5/97 (H3N2) and 
Bejing/262/95 (H1N1), and the influenza B IgG ELISA 
whole inactivated influenza virus B Hongkong/5/72 as 
antigens in pre-coated microtitration strips. The anti-
gen solutions contained high amounts of conserved 
influenza type-specific nucleo- and matrix proteins. 
Testing of sera was carried out at the dilution of 1:100 
according to the manufacturer’s instructions. Results 
were assessed on the basis of a standard curve calcu-
lated from three to four calibrators including positive 
and negative controls. In the influenza A IgG ELISA, 
samples were considered positive if the antibody 
concentration was calculated as >12 U/mL, a range of 
8–12 U/mL was considered equivocal and <8 U/mL was 
interpreted as negative. For the influenza B IgG ELISA, 
samples were considered positive if the antibody con-
centration was calculated as ≥22 relative units (RU) 
per mL, a range of ≥16 to <22 RU/mL was considered 
equivocal, and <16 RU/mL was interpreted as negative. 
Statistical analysis
A sample size of about 150 subjects per pre-defined age 
group was planned to assure that a single two-sided 
95% confidence interval (CI) for the prevalence of influ-
enza A and B IgG antibodies would deviate at most 8% 
from the observed value for a prevalence range of 5% 
to 95%. When regional differences were analysed, less 
precise seroprevalences obtained from single paediat-
ric centres resulted from small sample size. Antibody 
prevalence was calculated using the number of sero-
positive cases divided by the number of all subjects 
tested. Assuming binominal distribution, the two-sided 
exact 95% CI was calculated. The Cochran–Armitage 
test for trend [24] was used to examine the increase 
of antibody prevalence by age. Age-adjusted sex differ-
ences in antibody prevalence were investigated by the 
Mantel–Haenszel test [25]. Logistic regression odds 
ratios evaluated by the Wald statistics were used to 
compare age-specific prevalence of the children with 
the prevalence of the adult group as the whole. 
Age- and sex-specific antibody concentrations were 
described by mean and standard deviation (SD). The 
association of age and sex, and the concentration of 
antibodies were analysed using linear multiple regres-
sion. Antibody concentrations of the different age 
groups of children were compared with the correspond-
ing data of the whole adult group by the Dunnett test 
[26]. For both analyses, antibody concentration was 
transformed by the common logarithm. The level of sig-
nificance was 0.05 (two-sided). The SAS V9.2 software 
was used for statistical analyses.
Results
Prevalence and concentrations 
of influenza A virus IgG
The prevalence of IgG antibodies against influenza A 
virus in the samples tested is shown in Table 1. The 
overall prevalence of antibodies against influenza A 
virus was 87.6% (95% CI: 85.9–89.2) in the tested chil-
dren aged 0–17 years; among the tested blood donors, 
Table 2
Regional distribution of influenza A and B seroprevalence in children (aged 0–17 years, n=1,665) of nine German paediatric 
or diagnostic centres, 2008–10
Center
(Number of sera) Mean age in years
Seroprevalence in percentage (95% CI)
Influenza A Influenza B
Wuppertal (366) 9.6 90.7 (87.3–93.5) 49.5 (44.2–54.7)
Bremen (268) 8.3 81.7 (76.6–86.2) 34.7 (29.0–40.7)
Ulm (278) 8.2 81.7 (76.6–86.2) 51.4 (45.4–57.5)
Mannheim (225) 8.4 89.3 (84.6–93.1) 48.4 (41.8–55.2)
Würzburg (140) 9.9 97.9 (93.9–99.6) 64.3 (55.8–72.2)
Krefeld (111) 11.2 98.2 (93.6–99.8) 46.9 (37.3–56.6)
Erfurt (108) 5.8 75.7 (66.5–83.5) 25.9 (18.0–35.3)
Berlin (85)  8.5 90.6 (82.3–95.9) 52.9 (41.8–63.4)
Munich (84) 9.1 89.3 (80.6–95.0) 50.0 (38.9–61.1)
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the overall prevalence of influenza A IgG antibodies 
was 96.3% (95% CI: 93.9–97.9). 
The regional distribution of the influenza A seropreva-
lence in children among the nine centres included in 
this study is shown in Table 2. The prevalence of anti-
bodies ranged from 75.7% (Erfurt) to 97.9% (Würzburg); 
mean age of the children differed between the centres. 
Figure 1 shows the age- and sex-specific prevalence of 
influenza A IgG in the tested children and adults (blood 
donors). Statistical analysis demonstrated that the anti-
body prevalence against influenza A virus increased sig-
nificantly with age in children (p<0.001) and decreased 
with age in adults (p=0.004). Adjusted to age, there 
were no significant differences between the prevalence 
of antibodies among boys and girls (p=0.576), but in 
blood donors a significantly higher prevalence was 
detected in women than in men (p=0.031). Children up 
to the age group of five to six years had a significantly 
lower prevalence of antibodies than the adult controls 
(0−2 and 3−4 years: p<0.001, 5−6 years: p=0.003). In 
children vaccinated against seasonal (p=0.002) or pan-
demic influenza (p=0.01), the number of positives was 
significantly higher (seasonal: 209/220, 95.0%; pan-
demic: 98/99, 99.0%) than in non-vaccinated children 
(seasonal: 1,029/1,176, 87.5%; pandemic: 1,140/1,296, 
88.0%).
In the study group of children, the mean concentration 
of antibodies against influenza A virus was calculated 
as 59.95 U/mL (SD: 46.04), and the adult controls had 
a mean antibody concentration of 72.02 U/mL (SD: 
39.90). Figure 2 shows the concentrations of antibod-
ies against influenza A virus by age and sex of the 
tested children and adults (blood donors). The anti-
body concentrations increased significantly with age 
during childhood (p<0.001) and declined with age in 
adults (p=0.041). In young adults of 18–29 years, the 
mean antibody concentration was 85.75 U/mL (SD: 
40.33) compared with 66.06 U/mL (SD: 38.67) in older 
adults of 46–65 years. Adjusted to age, no significant 
differences could be found between boys and girls 
(p=0.426) nor between men and women (p=0.300). 
Children up to the age group of five to six years had 
significantly lower concentrations of IgG antibodies 
against influenza A virus than the control group of 
adults (p<0.001), whereas the antibody concentrations 
Figure 1
Age- and sex-specific prevalence of IgG antibodies against influenza A and B virus in children (aged 0–17 years) and adults 
(blood donors aged 18–65 years), Germany, 2008–11 (n=2,065)
The bars show the 95% confidence intervals for the point of estimates.
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were significantly higher among the 11–12 (p<0.001), 
13–14 (p=0.001) and 15–17 (p<0.001) year-olds than 
among the adults. These data were not adjusted for 
vaccination status. 
Prevalence and concentrations 
of influenza B virus IgG
Table 3 shows the prevalence of antibodies against 
influenza B virus in the samples tested. In children, the 
overall prevalence was 47.0% (95% CI: 44.6–49.5), and 
in the blood donors, it was 98.0% (95% CI: 96.1–99.1). 
The regional distribution of influenza B seropreva-
lence in the nine centres is shown in Table 2. The low-
est prevalence of antibodies was found with 25.9% 
in the Erfurt group and the highest with 64.3% in the 
Würzburg group, and these prevalences were related to 
the mean age of the children in the different centres. 
The age- and sex-specific prevalences of influenza B 
IgG in the tested children and adults (blood donors) are 
shown in Figure 1. Statistical analysis demonstrated 
that the prevalence of antibodies against influenza B 
increased significantly with age in children (p<0.001) 
and adults (p=0.018). Adjusted to age, there were no 
significant differences between the prevalence of anti-
bodies as a function of sex for children (p=0.977) and 
adults (p=0.635). In all age groups of children, signifi-
cantly lower prevalence of antibodies was measured 
than in the adult controls (p<0.001). In the group of 
children vaccinated against seasonal influenza, the 
number of positives (146/220, 66.4%) was significantly 
higher than in the group of non-vaccinated children 
(497/1,176, 42.3%, p<0.001).
The mean antibody concentrations against influenza B 
virus were estimated as 54.67 RU/mL (SD: 55.30) in the 
study group of children and as 119.31 RU/mL (SD: 44.97) 
in the control group of adults (blood donors). Figure 2 
shows the concentrations of influenza B-specific anti-
bodies depending on age and sex of the tested chil-
dren and adults (blood donors). The concentrations of 
antibodies increased with age up to the 15–17 year-olds 
(p<0.001), but there were no significant differences 
between the three age groups of adults (p=0.228). 
The antibody concentrations were not dependent on 
sex neither in the children (p=0.317) nor in the adults 
(p=0.892). For all age groups of children, significantly 
Figure 2
Age- and sex-specific distribution of IgG antibody concentrations against influenza A and B virus in children (aged 0–17 
years) and adults (blood donors aged 18–65 years), Germany 2008–11 (n=2,065)
The bars show the standard deviation for the point of estimates.
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lower antibody concentrations were measured com-
pared with the control group of adults (p<0.001).
Discussion
In this study, it was of particular interest to determine 
influenza seroprevalence of children up to the age of 
17 years in Germany. To obtain data most widely rep-
resentative for the whole population of children in 
Germany, nine different German regions were included. 
A recently published study on the influenza seropreva-
lence in Germany included only sera from children who 
lived in the German federal state Thuringia [2], and the 
results were not regarded as representative for the 
entire country. Furthermore, as that study used other 
serological methods than ours, the results are only 
comparable to a limited extent.
To date, the haemagglutination inhibition test or 
microneutralisation assays are the gold standards to 
determine IgG antibodies to influenza viruses in sero-
prevalence studies, and the only current correlate of 
immunity to influenza A and B is based on haemag-
glutination inhibition titre [17,18,27]. However, these 
assays are even virus strain- or lineage- and subtype-
specific, and studies carried out with a limited or poorly 
chosen panel of viral antigens may underestimate the 
true seroprevalence [28]. Furthermore, these assays 
are not suitable for large-scale studies because they 
are labour-intensive, time-consuming, not amenable 
to automation and not commercially available. Thus, 
sensitive and specific ELISAs mainly targeting con-
served type-specific antibodies against the influenza 
virus nucleo- and matrix proteins have been used suc-
cessfully in several studies for the determination of 
influenza seroprevalence in humans as well as pigs 
[2,22,28]. An essential prerequisite is, however, that 
the ELISAs used are evaluated for their performance 
characteristics. The ELISAs in the present study used 
inactivated influenza A and B viruses containing high 
amounts of conserved influenza type-specific nucleo- 
and matrix proteins and were selected because of 
their high sensitivity and specificity. Higher antibody 
titres measured in the vaccinated group suggest that 
the assays detected also IgG antibodies induced by 
vaccination against seasonal and pandemic influenza. 
That is why the vaccination coverage was analysed, but 
the proportion of vaccinated children was equally low 
in all regions, and the vaccination rate in adults could 
be assumed to be low [20]. Vaccination coverage was 
therefore not of significance for our findings. A limita-
tion of this study is that while the ELISAs indicate a 
previous infection, they provide no information about 
the time of infection. Antibodies to influenza virus 
nucleo- and matrix protein antigens fail to contribute to 
protection, but they indicate the presence of subtype-
independent T-cell-mediated protection [29]. 
In children, the overall prevalence of antibodies to 
influenza A was 87.6%, reflecting the epidemiologi-
cal dominance of seasonal and pandemic influenza A 
over influenza B between 2007 and 2010 in Germany 
[30-32], and assuming that antibodies persist at least 
six months after infection or vaccination [23]. The sero-
prevalence showed an age-dependent increase until 
Table 3
Prevalence of IgG antibodies against influenza B virus in children (aged 0–17 years, n=1,665) and adults (blood donors aged 
18–65 years, n=400), Germany, 2008–11
Age group 
in years
Male Female Male and female
Number of positive 
samples/total 
number
Percentage  
(95% CI)
Number of positive 
samples/total 
number
Percentage  
(95% CI)
Number of positive 
samples/total 
number
Percentage  
(95% CI)
Infants, children and adolescents
0–2 18/151 11.9 (7.2–18.2) 6/121 5.0 (1.8–10.5) 24/272 8.8 (5.7–12.8)
3–4 13/104 12.5 (6.8–20.4) 11/71 15.5 (8.0–26.0) 24/175 13.7 (9.0–19.7)
5–6 19/74 25.7 (16.2–37.2) 15/77 19.5 (11.3–30.1) 34/151 22.5 (16.1–30.0)
7–8 35/89 39.3 (29.1–50.3) 30/86 34.9 (24.9–45.9) 65/175 37.1 (30.0–44.8)
9–10 50/97 51.5 (41.2–61.8) 56/95 58.9 (48.4–68.9) 106/192 55.2 (47.9–62.4)
11–12 62/100 62.0 (51.8–71.5) 67/101 66.3 (56.3–75.4) 129/201 64.2 (57.1–70.8)
13–14 77/112 68.8 (59.3–77.2) 89/112 79.5 (70.8–86.5) 166/224 74.1 (67.9–79.7)
15–17 100/113 88.5 (81.1–93.7) 135/162 83.3 (76.7–88.7) 235/275 85.5 (80.7–89.4)
Total 374/840 44.5 (41.1–48.0) 409/825 49.6 (46.1–53.0) 783/1,665 47.0 (44.6–49.5)
Adults (blood donors)
18–29 75/79 94.9 (87.5–98.6) 70/72 97.2 (90.3–99.7]) 145/151 96.0 (91.6–98.5)
30–45 71/72 98.6 (92.5–100.0) 51/52 98.1 (89.7–100.0) 122/124 98.4 (94.3–99.8)
46–65 78/78 100.0 (95.4–100.0) 47/47 100.0 (92.5–100.0) 125/125 100.0 (97.1–100.0)
Total 224/229 97.8 (95.0–99.3) 168/171 98.2 (95.0–99.6) 392/400 98.0 (96.1–99.1)
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the age of nine to 10 years, when nearly all children 
had developed antibodies against influenza A virus. 
These data correlate well with the results published 
recently for children in the Netherlands [18]. The lat-
ter study was carried out with the haemagglutination 
inhibition test and showed that all children seven years 
and older had antibodies to at least one of six repre-
sentative influenza A(H3N2) and six representative 
influenza A(H1N1) virus strains selected for serological 
testing. Our data demonstrate that children, starting 
with the age of nine years, have a good basal immunity 
to influenza A. Thus, these children are at lower risk 
for potentially severe primary influenza infections and 
do not need a second dose of the vaccine against influ-
enza A as long as they have received the first vaccine 
dose. This is in agreement with findings published pre-
viously [33]. In contrast to the influenza seroprevalence 
in older children, nearly 40% of children under the age 
of four years had no influenza A virus-specific IgG anti-
bodies. These children are immunologically naïve, and 
therefore have to be regarded as susceptible to poten-
tially severe primary influenza A infection. Accordingly, 
Bodewes et al. [18] found the highest attack rates with 
primary influenza A infections, calculated on the basis 
of antibody prevalence, in children two and three years 
of age. In addition, children up to the age of six years 
in our study had a significantly lower influenza A sero-
prevalence and significantly lower antibody concentra-
tions against influenza A virus than adults. This is most 
likely due to the lower number of boosting influenza A 
infections in their lifetime [2]. Adolescents at the age 
of 13 to 14 years had significantly higher influenza A 
seroprevalence, and 11 to 17 year-olds had significantly 
higher antibody concentrations to influenza A virus 
than adults. These data, which correspond to results 
reported previously [2], may suggest that these age 
groups have the highest attack rates of influenza A re-
infections or more frequent silent boosting. However, 
the lower seroprevalence in adults might also be due 
to faster waning of immunity in older people. Among 
the adults, the antibody prevalence against influenza 
A virus was significantly higher in women than in men. 
These findings may be associated with the high inci-
dence of influenza A during childhood since care of 
children in Germany is generally undertaken by women 
[34]. Since there was no information about the influ-
enza vaccination status of our study participants, it 
remained unclear whether the higher prevalence of 
anti-influenza A antibodies may reflect a difference in 
vaccination status. 
A different pattern was observed for the seropreva-
lence of influenza B. The overall prevalence of antibod-
ies to influenza B in children was 47%. Approximately 
60–70% of all children up to the age of 12 years were 
serologically naïve and have to be considered suscepti-
ble to influenza B. By the age of 18 years, an influenza 
B seroprevalence of approximately 90% was reached. 
The considerably lower seroprevalence rate of 25% 
among 12 year-old children reported in our recent 
study [2], can only be interpreted in the context of the 
single test population from Thuringia and the differ-
ent serological method used. In the present study, the 
group of all children and adolescents had significantly 
lower influenza B seroprevalences and significantly 
lower antibody concentrations against influenza B than 
adults. They seem to have had fewer infections dur-
ing their lifetimes than adults [2]. It can be concluded 
from the current study that a natural immunity against 
influenza B at a level comparable to influenza A, is only 
established around the age of 18 years. Since children 
with incomplete specific immunity may be at risk for 
severe courses of influenza B [35,36] a seasonal vac-
cination against influenza B could benefit all children. 
In Germany, there are obvious regional differences in 
seroprevalences of influenza B. As the present study 
shows, the influenza B seroprevalences of distinct 
German regions differ in children with a mean age of 
eight to 10 years between approximately 35% and 65%, 
i.e. by as much as 30%. By contrast, the overall values 
of influenza A seroprevalence varied by as much as 
approximately 16% (range: 82–98%). This means that 
influenza B outbreaks, contrary to influenza A epidem-
ics, may often be restricted to certain local regions. 
Multicentre studies are required to obtain representa-
tive seroprevalence data. Different rates of influenza 
vaccination may be of importance, but data on this are 
not available. Interestingly, the lowest seroprevalence 
of influenza B of this study was observed with 25.9% 
in the child population with a mean age of six years, 
recruited from the paediatric clinic in Erfurt, the capi-
tal of the German federal state Thuringia. Sera from 
children 18 years and younger in this region had been 
included in our previous study resulting in an overall 
influenza B seroprevalence of 9.6% [2]. Reasons for 
this variation can be differences between the serologi-
cal methods used and the test populations. This means 
that the methods used in seroprevalence studies must 
be validated thoroughly.
In conclusion, this study provides representative data 
of influenza A and B seroprevalences in children aged 
up to the age of 17 years in Germany. They may have 
implications for the development of vaccination strate-
gies to protect children against influenza A and B.
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